Cited by 73Schizophrenia research and treatmentMental Health and PsychiatryNeurotransmitter Receptor Influence on Behavior

D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia

Open access
Gottlieb, Jennifer D., Cather, Corinne, Shanahan, Meghan, Creedon, Timothy, Macklin, Eric A., Goff, Donald C.·2011·Schizophrenia Research

Abstract

Glutamatergic N-methyl-D-aspartate (NMDA) receptor hypofunction has been proposed as a mechanism underlying psychosis. D-cycloserine, a partial agonist at the glycine site of the NMDA receptor, enhances learning in animal models, although tachyphylaxis develops with repeated dosing. Once-weekly dosing of D-cycloserine produces persistent improvement when combined with cognitive behavioral therapy (CBT) in anxiety disorders. Delusional beliefs can be conceptualized as a learning deficit, characterized by the failure to use contradictory evidence to modify the belief. CBT techniques have been developed with modest success to facilitate such reality-testing (or new learning) in delusional beliefs. The current study evaluated whether D-cycloserine could potentiate beneficial effects of CBT on delusional severity. Twenty-one outpatients with schizophrenia or schizoaffective disorder and moderately severe delusions were randomized in a double-blind cross-over design to receive a single-dose of either D-cycloserine 50mg or placebo in a counterbalanced order on two consecutive weeks 1h prior to a CBT intervention involving training in the generation of alternative beliefs. Assessments were completed at baseline, 7 days following the first study drug administration and 7 days following the second study drug administration. Contrary to prediction, there was no significant d-cycloserine treatment effect on delusional distress or severity as measured by the SAPS or PSYRATS. An unexpected finding was an order effect, whereby subjects who received D-cycloserine first had significantly reduced delusional severity, distress, and belief conviction on PSYRATS compared to subjects who received placebo first. However, this finding is consistent with animal models in which D-cycloserine enhances learning only when accompanying the first exposure to training.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.schres.2011.05.029

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a 2011 study, participants who received D-cycloserine after cognitive behavioural therapy showed greater adoption of new explanatory beliefs than those who received placebo.

    “In a 2011 investigation 24 , participants given D-cycloserine (which boosts NMDA receptor function) after cognitive behavioural therapy showed an enhanced adoption of new explanatory beliefs compared with those who received placebo.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
Corresponding author
Gottlieb, Jennifer D.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2011-09
Volume
131
Issue
1-3
Pages
69-74
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2052868558
Cited by
73
References
26
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 5 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 7 · 2017: 2 · 2016: 6 · 2015: 7 · 2014: 10 · 2013: 7 · 2012: 9
FWCI
5.91
Type
journal article
Language
en
Open access
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (P50MH060450, K24MH002025, 5 P50 MH60450-11)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
D-cycloserine, cognitive behavioral therapy
MeSH terms
Adolescent, Adult, Aged, Antimetabolites, Culture, Cycloserine, Delusions, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders, Retrospective Studies, Schizophrenia, Cognitive Behavioral Therapy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review